Compare ZYME & LC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZYME | LC |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2022 | 2008 |
| Metric | ZYME | LC |
|---|---|---|
| Price | $23.23 | $14.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $32.75 | $22.67 |
| AVG Volume (30 Days) | 484.1K | ★ 2.5M |
| Earning Date | 03-30-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.81 | ★ 157.78 |
| EPS | N/A | ★ 1.16 |
| Revenue | $76,304,000.00 | ★ $314,702,000.00 |
| Revenue This Year | $63.10 | N/A |
| Revenue Next Year | $93.26 | $15.91 |
| P/E Ratio | ★ N/A | $14.42 |
| Revenue Growth | ★ 0.38 | N/A |
| 52 Week Low | $9.03 | $7.90 |
| 52 Week High | $28.49 | $21.67 |
| Indicator | ZYME | LC |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 39.56 |
| Support Level | $22.22 | $14.88 |
| Resistance Level | $23.66 | $17.57 |
| Average True Range (ATR) | 0.84 | 0.94 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 45.85 | 8.40 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.